Nokia Q2 Highlights; 3% Topline Decline, Apple Partnership And Strong Enterprise Performance

Nokia Corp (NYSE: NOK) reported a second-quarter FY23 net sales decline of 3% year-on-year (0% in constant currency) to €5.71 billion ($6.22 billion), missing the consensus of $6.38 billion.

Nokia Corp (NYSE:NOK) reported a second-quarter FY23 net sales decline of 3% year-on-year (0% in constant currency) to €5.71 billion ($6.22 billion), missing the consensus of $6.38 billion.

Network Infrastructure sales declined by 6% Y/Y in CC. Cloud and Network Services sales increased by 2% Y/Y in CC, while Nokia Tech grew by 10% Y/Y benefiting from €80 million of catch-up net sales.

Mobile Networks sales grew by 5% Y/Y in CC as 5G deployments in India ramped up. 

Margins: Gross margin declined by 200 bps to 38.2%. Comparable gross margin decreased by 180 bps to 38.8% due to regional mix in Mobile Networks.

The operating margin decreased by 130 bps to 8.3%, and the comparable operating margin declined by 120 bps to 11.0%.

EPS was €0.05, and comparable EPS was €0.07 ($0.076), missing the consensus of $0.08.

Nokia held €5.1 billion in cash and equivalents and used €0.4 billion in free cash flow.

Dividend: The board proposed a quarterly dividend of €0.03 per share. 

The quarter’s highlight was the new long-term patent license agreement signed with Apple Inc (NASDAQ:AAPL). Nokia’s performance in Enterprise was also a highlight, with net sales increasing by 27% in constant currency. 

FY23 Outlook: As announced on July 14, 2023, Nokia now expects full-year 2023 net sales of EUR 23.2 billion- EUR 24.6bn with a comparable operating margin of 11.5%-13.0%.

Price Action: NOK shares traded lower by 0.25% at $3.93 premarket on the last check Thursday.

Total
0
Shares
Related Posts
Read More

Neurocrine Biosciences Presents Data At MDS International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Comparable Improvement Over Time In Tardive Dyskinesia Severity And Impact Following Treatment With INGREZZA Capsules

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today presented findings from a data analysis of KINECT®-4 demonstrating a comparable pattern of improvement over time of clinician-rated tardive dyskinesia (TD)

NBIX